Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade

被引：2

作者：

Ree, Anne Hansen ^{[1
,2
]}

Hoye, Eirik ^{[2
,3
]}

Esbensen, Ying ^{[2
,4
]}

Beitnes, Ann-Christin R. ^{[5
]}

Negard, Anne ^{[2
,6
]}

Bernklev, Linn ^{[2
,7
]}

Tetlie, Linn Kruse ^{[8
]}

Fretland, Asmund A. ^{[9
,10
]}

Hamre, Hanne M. ^{[1
]}

Kersten, Christian ^{[1
,11
]}

Hofsli, Eva ^{[12
,13
]}

Guren, Marianne G. ^{[2
,14
]}

Sorbye, Halfdan ^{[15
,16
]}

Nilsen, Hilde L. ^{[2
,17
]}

Flatmark, Kjersti ^{[2
,18
]}

Meltzer, Sebastian ^{[1
]}

机构：

[1] Akershus Univ Hosp, Dept Oncol, N-1478 Lorenskog, Norway

[2] Univ Oslo, Inst Clin Med, Oslo, Norway

[3] Oslo Univ Hosp, Dept Tumor Biol, Oslo, Norway

[4] Akershus Univ Hosp, Dept Clin Mol Biol, Lorenskog, Norway

[5] Akershus Univ Hosp, Dept Pathol, Lorenskog, Norway

[6] Akershus Univ Hosp, Dept Radiol, Lorenskog, Norway

[7] Akershus Univ Hosp, Dept Gastroenterol, Lorenskog, Norway

[8] Sorlandet Hosp, Dept Oncol, Kristiansand, Norway

[9] Oslo Univ Hosp, Intervent Ctr, Oslo, Norway

[10] Oslo Univ Hosp, Dept Hepatopancreato Biliary Surg, Oslo, Norway

[11] Sorlandet Hosp, Dept Res, Kristiansand, Norway

[12] St Olavs Hosp, Dept Oncol, Trondheim, Norway

[13] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway

[14] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[15] Haukeland Hosp, Dept Oncol, Bergen, Norway

[16] Univ Bergen, Dept Clin Sci, Bergen, Norway

[17] Oslo Univ Hosp, Dept Microbiol, Oslo, Norway

[18] Oslo Univ Hosp, Dept Gastroenterol Surg, Oslo, Norway

来源：

ONCOIMMUNOLOGY | 2024年 / 13卷 / 01期

关键词：

BRAF mutation; colorectal cancer; immune checkpoint blockade; metastasis; microsatellite-stable; oxaliplatin; T-cell receptor; IMMUNOTHERAPY; LIVER;

D O I：

10.1080/2162402X.2024.2372886

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB). Three of 38 patients assigned to this experimental treatment had metastases from BRAF-mutant MSS-CRC, in general a poor-prognostic subgroup explored here. The >= 70-year-old females presented with ascending colon adenocarcinomas with intermediate tumor mutational burden (6.2-11.8 mutations per megabase). All experienced early disappearance of the primary tumor followed by complete response of all overt metastatic disease, resulting in progression-free survival as long as 20-35 months. However, they encountered recurrence at previously unaffected sites and ultimately sanctuary organs, or as intrahepatic tumor evolution reflected in the terminal loss of initially induced T-cell clonality in liver metastases. Yet, the remarkable first-line responses to short-course oxaliplatin-based chemotherapy alternating with ICB may offer a novel therapeutic option to a particularly hard-to-treat MSS-CRC subgroup.

引用

页数：7